[1]陈 慎,郑水华,易素芳,等.乙肝肝硬化患者血清HBsAg与HBVDNA比值在不同病程差异及疗效价值研究[J].现代检验医学杂志,2018,33(04):39-42/46.[doi:10.3969/j.issn.1671-7414.2018.04.010]
　CHEN Shen,ZHENG Shui-hua,YI Su-fang,et al.Difference of the Ratio of HBsAg to HBV DNA in Patients with Different Severity of Chronic Hepatitis B Virus Infection and Predictive Value for Clinical Effects[J].Journal of Modern Laboratory Medicine,2018,33(04):39-42/46.[doi:10.3969/j.issn.1671-7414.2018.04.010]
点击复制

乙肝肝硬化患者血清HBsAg与HBVDNA比值在不同病程差异及疗效价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年04期
页码:
39-42/46
栏目:
论著
出版日期:
2018-08-30

文章信息/Info

Title:
Difference of the Ratio of HBsAg to HBV DNA in Patients with Different Severity of Chronic Hepatitis B Virus Infection and Predictive Value for Clinical Effects
文章编号:
1671-7414(2018)04-039-05
作者:
陈 慎; 郑水华; 易素芳; 田文芳
珠海市中西医结合医院 珠海市第二人民医院,广东珠海 519000
Author(s):
CHEN Shen; ZHENG Shui-hua; YI Su-fang; TIAN Wen-fang
Zhuhai Integrated Chinese and Western Medicine Hospital, Zhuhai Second People's Hospital,Guangdong Zhuhai 519000,China
关键词:
乙型肝炎表面抗原;  乙型肝炎病毒;  慢性乙型肝炎;  乙型肝炎肝硬化
分类号:
R512.62; R446.6
DOI:
10.3969/j.issn.1671-7414.2018.04.010
文献标志码:
A
摘要:
目的 研究分析乙型肝炎表面抗原(HbsAg)与乙型肝炎病毒(HBV)DNA比值在不同严重程度慢性乙型肝炎(CHB)病毒感染患者中差异及其对疗效的预测价值。方法 选取该院33例轻中度CHB者为A组、41例重度CHB者为B组和38例乙型肝炎肝硬化者为C组。对各组患者总胆红素(TBIL)和谷氨酸氨基转移酶(ALT)等指标的水平进行检测,并对其HBsAg,HBV DNA进行检测。结果 ①C组HBsAg,HBV DNA较A,B组均显著降低(P<0.05),而三组间HBsAg与HBV DNA比值的比较,差异无统计学意义(P>0.05); ②A组与B组HBsAg,HBV DNA,HBsAg与HBV DNA比值的比较,差异均无统计学意义(P>0.05)。③完全应答组治疗后3个月HBsAg,HBV DNA较治疗前均显著降低,差异有统计学意义(P<0.05),HBsAg与HBV DNA比值较治疗前显著升高(P<0.05)。④部分应答组、无应答组治疗后3个月HBsAg与治疗前比较,均无统计学意义(P>0.05),而HBV DNA较治疗前均显著降低(P<0.05)。⑤HBsAg与HBV DNA比值较治疗前均显著升高(P<0.05)。⑥相比HBsAg(0.54),HBV DNA(0.42),HBsAg与HBV DNA比值预测临床疗效的ROC曲线下面积(0.67)显著升高。结论 乙型肝炎肝硬化患者HBsAg与HBV DNA比值明显高于CHB患者,并且该比值对疗效的预测价值明显高于HBsAg,HBV DNA。
Abstract:
Abstract:Objective To analyze the differences of the ratio of hepatitis B surface antigen(HBsAg)to hepatitis B virus(HBV)DNA inpatients with different severity of chronic hepatitis B(CHB)virus infection and prediction value for curative effects.Methods 33 patients with mild and moderate CHB were selected as the group A,41 patients with severeCHB as the group B and 38 patients with hepatitis B cirrhosis as the group C.The levels of total bilirubin(TBIL)and glutamic acid transaminase(ALT)and other indexes were detected in each group,and the levels of HBsAg and HBV DNA weredetected.Results The HBsAg and HBV DNA in the group C were significantly lower than those in the group A and group B(P<0.05),andthe ratio of HBsAg and HBV DNA showed no significant difference among those three groups(P>0.05); the HBsAg,HBV DNA and the ratio of HBsAg to HBV DNA inthe group A and group B showed no significant difference(P>0.05).The HBsAg and HBV DNA in the complete response group at 3 months after treatment were significantly lower than those before treatment(P<0.05),and the ratio of HBsAg to HBV DNA was significantly higher than that before treatment(P>0.05).The HBsAg in the partial response group and non-response group 3 months aftertreatment showed no significant difference in comparison of before treatment(P>0.05),while the HBV DNA were significantly lower than before treatment(P<0.05),and the ratio of HBsAg to HBV DNA were significantly higher than before treatment(P<0.05).Compared with HBsAg(0.54)and HBV DNA(0.42),the area under the ROC curve of the ratio of HBsAg to HBV DNA(0.67)predicting the clinical efficacy was significantly increased.Conclusion The ratio of HBsAg to HBV DNA in patients with hepatitis B cirrhosis is significantly higher than that of CHB patients,and the predictive value of the ratio is significantly higher than that of HBsAg and HBV DNA.

参考文献/References:

[1] Buti M,Tsai N,Petersen J,et al.Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virusinfection[J].Digestive Diseases and Sciences,2015,60(5):1457-1464.
[2] Schweitzer A,Horn J,Mikolajczyk RT,et al.Estimations of worldwide prevalence of chronic hepatitis B virus infection:a systematic review of data published between 1965 and 2013[J].The Lancet,2015,386(10003):1546-1555.
[3] 黄明清,胡 丽,咸建春.慢性乙型肝炎病毒感染患者表面抗原定量检测与病毒载量的相关性[J].中华医院感染学杂志,2013,23(14):3314-3316. Huang MQ,Hu L,Xian JC.Relationship between detection of surface antigen quantity at different phases and viral load of patients with chronic hepatitis B virus infection[J].China J Nosocomio,2013,23(14):3314-3316.
[4] Denniston MM,Jiles RB,Drobeniuc J,et al.Chronic hepatitis C virus infection in the United States,national health and nutrition examination survey 2003 to 2010[J].Annals of Internal Medicine,2014,160(5):293-300.
[5] 孔媛媛,尤 红,贾继东,等.世界卫生组织《慢性乙型肝炎病毒感染预防、关怀和治疗指南》制定方法学和核心建议点评[J].中华肝脏病杂志,2015,23(7):485-487. Kong YY,You H,Jia JD,et al.Commentary on key recommendations andguidelines development methodology of world health organization guidelines forprevention,care and treatment of persons with chronic Hepatitis B infection[J].The Chinese Journal of Hepatology,22015,23(7):485-487.
[6] Gordon SC,Lamerato LE,Rupp LB,et al.Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population[J].Clinical Gastroenterology and Hepatology,2014,12(5):885-893.
[7] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华传染病杂志,2011,29(2):65-80. Chinese Society of Hepatology and Chinese Society Infectious Diseases Chinese Medical Association.The guidelines of prevention and treatment for chronic hepatitis B(2010 Version)[J].Chinese Journal of Infectious Diseases,2011,29(2):65-80.
[8] Rehermann B,Bertoletti A.Immunological aspects of antiviral therapy ofchronic hepatitis B virus and hepatitis C virus infections[J].Hepatology,2015,61(2):712-721.
[9] Trépo C,Chan HL,Lok A.Hepatitis B virus infection[J].The Lancet,2014,384(9959):2053-2063.
[10] 周红星,江应安.乙型肝炎病毒表面抗原在慢性乙型肝炎病毒感染后不同临床阶段的定量检测及临床意义[J].中国医师进修杂志,2014,37(24):15-18. Zhou HX,Jiang YA.Hepatitis B virus surface antigen quantitative value in different stages of chronic hepatitis B virus infection[J].Chinese Journal of Postgraduates of Medicine,2014,37(24):15-18.
[11] 周洪波,李晶媛,赵勇华,等.乙型肝炎病毒感染不同阶段HBsAg定量变化的研究[J].哈尔滨医科大学学报,2014,47(4):350-352. Zhou HB,Li JY,Zhao YH,et al.Quantitation of hepatitis B surface antigen(HBsAg)in the natural course of hepatitis B virus(HBV)infection[J].Journalof Harbin Medical University,2014,47(4):350-352.
[12] Wooddell CI,Rozema DB,Hossbach M,et al.Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection[J].Molecular Therapy,2013,21(5):973-985.
[13] 陆 伟,张占卿.血清乙型肝炎表面抗原水平预测慢性乙型肝炎病毒感染状态的研究进展[J].临床荟萃,2013,28(10):1185-1190. Lu W,Zhang ZQ.Progress in the prediction of chronic hepatitis B virus infection by serum hepatitis B surface antigen level[J].Clinical Am Focus,2013,28(10):1185-1190.
[14] McMahon BJ.Chronic hepatitis B virus infection[J].Medical Clinics North,2014,98(1):39-54.
[15] Gane EJ,Lim YS,Gordon SC,et al.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J].Journal of Hepatology,2015,63(2):320-328.
[16] 黄 允,李 艳,彭 锐,等.HBV感染致肝损伤患者CRP,hsCRP和SAA临床价值的探讨[J].现代检验医学杂志,2017,32(2):49-52. Huang Y,Li Y,Peng R,et al.Clinical significance of SAA CRP and hsCRP in HBV hepatopathy patients[J].Journal of Modern Laboratory Medicine,2017,32(2):49-52.

相似文献/References:

[1]王 森,黄太宏,高 硕,等.系统性红斑狼疮患者乙型肝炎病毒感染的分析研究[J].现代检验医学杂志,2016,31(01):41.[doi:10.3969/j.issn.1671-7414.2016.01.011]
　WANG Sen,HUANG Tai-hong,GAO Shuo,et al.Prevalence of Hepatitis B Virus Infection in Systemic Lupus Erythematosus Patients[J].Journal of Modern Laboratory Medicine,2016,31(04):41.[doi:10.3969/j.issn.1671-7414.2016.01.011]
[2]陈雪花,雷艳君.2003～2014年安康某高校新生乙肝病毒感染及免疫接种情况调查[J].现代检验医学杂志,2017,32(01):147.[doi:10.3969/j.issn.1671-7414.2017.01.041]
　CHEN Xue-hua,LEI Yan-jun.Investigation on the Freshmen' Status of the Preventive Vaccination Against Hepatitis B in A University of Ankang City in 2003～2014[J].Journal of Modern Laboratory Medicine,2017,32(04):147.[doi:10.3969/j.issn.1671-7414.2017.01.041]
[3]李育敏,徐 怡,阚丽娟,等.荧光定量PCR测定HBV DNA测量不确定度的评定与应用探讨[J].现代检验医学杂志,2019,34(03):151.[doi:10.3969/j.issn.1671-7414.2019.03.039]
　LI Yu-min,XU Yi,KAN Li-juan,et al.Investigation on the Estimation and Application of the Uncertainty ofHepatitis B Virus DNA Determination by Fluorescence Quantitative PCR[J].Journal of Modern Laboratory Medicine,2019,34(04):151.[doi:10.3969/j.issn.1671-7414.2019.03.039]
[4]吴　婕,张英杰,周华君,等.慢性HBV感染者血清持续低水平HBsAg表达免疫耐受机制的研究进展[J].现代检验医学杂志,2022,37(02):199.[doi:10.3969/j.issn.1671-7414.2022.02.040]
　WU Jie,ZHANG Ying-jie,ZHOU Hua-jun,et al.doi:10.3969/j.issn.1671-7414.2022.02.040 Research Progress on Immune Tolerance Mechanism of Persistent Low-level Serum HBsAg Expression in Patients with Chronic HBV Infection[J].Journal of Modern Laboratory Medicine,2022,37(04):199.[doi:10.3969/j.issn.1671-7414.2022.02.040]

备注/Memo

备注/Memo:
作者简介:陈 慎(1978-),男,本科,主管技师,研究方向:医学检验,E-mail:q151614@126.com。
更新日期/Last Update: 2018-08-16